DailyStocks Stock Article Search

https://www.zacks.com/stock/news/2249012/prestige-consumer-pbh-banks-on-its-portfolio-amid-cost-woes?cid=CS-ZC-FT-analyst_blog|zer_report_update-2249012 Apr 02, 2024 - Prestige Consumer (PBH) develops long-term partnerships across its diverse retail footprint and invests heavily in the e-commerce channel. 0

https://www.zacks.com/stock/news/2249322/abbott-s-abt-i-stat-tbi-cartridge-receives-fda-approval?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2249322 Apr 02, 2024 - Abbott's (ABT) i-STAT Alinity instrument uses whole blood to help assess patients with a suspected mild traumatic brain injury or concussion. 0

https://www.zacks.com/stock/news/2249828/here-s-why-you-should-retain-conmed-cnmd-stock-for-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2249828 Apr 03, 2024 - CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum. 0

https://www.zacks.com/stock/news/2249871/reasons-to-retain-pacbio-pacb-stock-in-your-portfolio-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2249871 Apr 03, 2024 - PacBio's (PACB) strong product demand and top-line growth raise optimism about the stock. 0

https://www.zacks.com/stock/news/2249829/veeva-systems-veev-cfo-resignation-sparks-6-stock-drop?cid=CS-ZC-FT-analyst_blog|price_surge_/_plunge-2249829 Apr 03, 2024 - Veeva Systems' (VEEV) CFO, Brent Bowman, steps down, causing a 6% stock price decline. Analysts weigh in on the impact and prospects for the cloud-solutions company. 0

https://www.zacks.com/stock/news/2250721/qiagen-qgen-boosts-cancer-research-suite-with-new-launches?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2250721 Apr 04, 2024 - QIAGEN's (QGEN) new products, coupled with the IVD version of QIAGEN's digital PCR platform QIAcuity, are planned to be released in mid-2024. 0

https://www.zacks.com/stock/news/2250638/reasons-to-add-cardinal-health-cah-to-your-portfolio-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2250638 Apr 04, 2024 - Cardinal Health (CAH) gains from a solid pharmaceutical segment and a diversified product portfolio. However, the rising cost of products is a concern. 0

https://www.zacks.com/stock/news/2250683/glaukos-gkos-idose-tr-receives-permanent-j-code-from-cms?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2250683 Apr 04, 2024 - Glaukos (GKOS) announces the receipt of a permanent J-code for iDose TR from the CMS, which is likely to boost the billing and payment process. 0

https://www.zacks.com/stock/news/2251310/angiodynamics-ango-alphavac-gets-fda-nod-for-pe-treatment?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2251310 Apr 05, 2024 - AngioDynamics (ANGO) announces the FDA's approval of its AlphaVac F1885 System, which is likely to expand the range of therapy alternatives available to pulmonary embolism patients. 0

https://www.zacks.com/stock/news/2251191/haemonetics-hae-new-teg-6s-cartridge-gets-fda-approval?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2251191 Apr 05, 2024 - Haemonetics' (HAE) TEG testing gives vital information that can assist doctors with better control of their patients' hemostasis. 0